| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60de6123396cd6baed2ebbaedebbbf79 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 |
| filingDate |
2015-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1986923e424902e9242f9f6474dae30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46b2dbff37358b0021143b171b2d4a6a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed9b4b03a00d56c4c65ed37c6b18c005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b62a3cc0275e396ea828dbe9ea4aa08d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0122c4f1f67c4fd3eeb76864f73a57d |
| publicationDate |
2017-01-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-201700095-A |
| titleOfInvention |
Sustained release oral preparation containing morphine and naloxone |
| abstract |
A sustained release oral preparation comprising morphine or a physiologically acceptable salt thereof and naloxone or a physiologically acceptable salt thereof for oral replacement therapy of an opioid dependent subject, each of the oral agents 100 mg of morphine contains 0.5 to 2 mg of narnosone. |
| priorityDate |
2015-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |